Ernie Tremblay’s teaser pitches about imminent FDA decisions or other biotech catalysts always get a lot of attention — not necessarily because he’s always right (ARLZ did get approval for their drug, but the stock is actually down… EARS did not “double by August 31” because the trial he was teasing failed on efficacy), but […]
Another month, another big pitch about a biotech stock with a great “P-Value Indicator” from Ernie Tremblay, all in an ad for his Biotech Insider Alert. Should we pay attention? Well, we can hardly avoid noticing it — we’re being battered about the head and neck with the constant email fusillade from Tremblay’s publisher and […]
Ernie Tremblay is the name behind the Biotech Insider Alert newsletter ($1,950/year) at Money Map Press, and his claim is that he has a “P-Value” formula that helps him to identify biotech stocks that are about to release good data that can send their shares soaring. I’m not going to get into the actual “formula” […]
This ad first showed up in our inboxes under the “end surgery forever” headline in late January, and the following article first appeaered on January 26. We have not gone through and updated the article, though the basic pitch is just about the same in the new version of the ad today as it was […]
Golly, most people who might subscribe to investment newsletters are baby boomers. And most of that generation is just a few years past their midlife crisis… so you can be pretty sure that a “silent epidemic” will get them to read your ad, yes? Apparently so, if the questions rolling in to Gumshoe HQ over […]
Heads up: I made a mistake on this one when it first went up on the site. We strive for at least a 99% accuracy rate in identifying teaser targets, and this is apparently my mistake for 2014. Thanks to several readers for alerting me to the fact that I moved too quickly in posting […]
I know a great many of the Irregulars have been interested in FDA dates recently, partly thanks to the community of biotech enthusiasts who have coalesced around the musings of our own Dr. KSS, so I thought I’d spin out a quick answer to you for a teaser pitch that’s been sent out quite breathlessly […]
Newsletter/trading service that aims to track important trading catalyst dates for biotech stocks, including FDA approvals and submissions and clinical trial data releases. Formerly called BioScience Millionaire.